|Application ||WB, IHC-P, IHC-F, IF, FC, Func|
|Calculated MW||32462 Da|
|Purification||Purified IgG prepared by ion exchange chromatography.|
|Immunogen||U266 cell line.|
|Shelf Life||18 months from date of despatch.|
|Other Names||Syndecan-1, SYND1, CD138, SDC1, SDC|
|Target/Specificity||Mouse anti-human CD138 antibody, clone B-A38 recognizes human CD138, also known as Syndecan-1 (SDC-1). CD138 is a member of the transmembrane heparan sulfate proteoglycan family (O’Connellet al.2004,Sandersonet al.2008). It is composed of a core protein (comprising 3 domains; a short cytoplasmic domain, a transmembrane domain, and a long extracellular domain) and covalently attached heparan sulfate chains (Sandersonet al.2008).Syndecan-1 is expressed on the surface of plasma cells within the hematopoietic system and on the surface of mature epithelial cells (O’Connellet al.2004). It acts as an extracellular matrix receptor, involved in many cellular functions, including cell binding, cell signalling and cytoskeletal organization through cell-cell adhesion and cell-matrix adhesion (Sandersonet al.2008).|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human CD138 Antibody, clone B-A38 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Borset, M. et al. (1993) Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation.Br J Haematol. 85 (3): 446-51. 2. Du, S. et al. (2010) Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma.Int J Clin Exp Pathol. 3 (4): 448-57. 3. Kylänpää, L. et al. (2009) Syndecan-1 and tenascin expression in cystic tumors of the pancreas.JOP. 10 (4): 378-82. 4. Beauvais, D.M. et al. (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor.J Exp Med. 206: 691-705. 5. Beauvais, D.M. and Rapraeger, A.C. (2010) Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activationJ Cell Sci. 123: 3796-807. 6. Kim, Y.C. et al. (2010) Presence of Porphyromonas gingivalis and plasma cell dominance in gingival tissues with periodontitis.Oral Dis. 16: 375-81. 7. Chang, H. et al. (2010) CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.Haematologica. 95: 1542-7. 8. Mahshid, Y. et al. (2009) High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes.BMC Immunol. 2009 Jan 9;10:2. 9. Guedez, L. et al. (2005) Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.Blood. 105: 1660-8. 10. Li, K. et al. (2010) Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature.Int J Clin Exp Pathol. 4: 190-6. 11. Yang, Y. et al. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.Blood. 110: 2041-8. 12. Thaunat, O. et al. (2010) Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis.J Immunol. 185: 717-28. 13. Cannizzo, E. et al. (2012) The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.Am J Clin Pathol. 137 (3): 377-86. 14. Li, K. et al. (2012) A rare and unique case of aggressive IgE-? plasma cell myeloma in a 28-year-old woman presented initially as an orbital mass.Hum Pathol. 43: 2376-84. 15. Christianson, H.C. et al. (2013) Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity.Proc Natl Acad Sci U S A. 110 (43): 17380-5. 16. Malminen, M. et al. (2002) Functional expression of NF1 tumor suppressor protein: association with keratin intermediate filaments during the early development of human epidermis.BMC Dermatol. 2: 10. 17. Itoua Maïga, R. et al. (2014) Flow cytometry assessment of in vitro generated CD138+ human plasma cells.Biomed Res Int. 2014: 536482. 18. Di Niro, R. et al. (2016) Responsive population dynamics and wide seeding into the duodenal lamina propria of transglutaminase-2-specific plasma cells in celiac disease.Mucosal Immunol. 9 (1): 254-64. 19. Yigit, N. et al. (2015) Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Hum Pathol. 46 (8): 1217-25. 20. Lum, D. & Wong, K.P. (2006) Sarcomatoid plasmacytoma: a diagnosis not often considered.Pathology. 38 (6): 593-596. 21. Gill, J. et al. (2009) A case of hyperIgG4 disease or IgG4-related sclerosing disease presenting as retroperitoneal fibrosis, chronic sclerosing sialadenitis and mediastinal lymphadenopathy.Pathology. 41 (3): 297-300. 22. Adepu, S. et al. (2015) Incipient renal transplant dysfunction associates with tubular syndecan-1 expression and shedding.Am J Physiol Renal Physiol. 309 (2): F137-45.1. Anttonen, A. et al. (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma.Br J Cancer. 79 (3-4): 558-64.2. O'Connell, F.P. et al. (2004) CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.Am J Clin Pathol. 121:254-63.3. Sanderson, R.D. et al. (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment.Clin Exp Metastasis. 25:149-59.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.